相关实验视频

Updated: Jun 14, 2025

A Direct, Regioselective and Atom-Economical Synthesis of 3-Aroyl-N-hydroxy-5-nitroindoles by Cycloaddition of 4-Nitronitrosobenzene with Alkynones

A Direct, Regioselective and Atom-Economical Synthesis of 3-Aroyl-N-hydroxy-5-nitroindoles by Cycloaddition of 4-Nitronitrosobenzene with Alkynones

Published on: January 21, 2020

发现和优化N-Heteroaryl IndazoleLRRK2抑制剂的发现和优化

Kaitlyn M Logan¹, Will Kaplan¹, Vladimir Simov¹

¹Merck & Co., Inc., 33 Avenue Louis Pasteur, Boston, Massachusetts 02115, United States.

Journal of medicinal chemistry

|September 4, 2024

概括

研究人员为帕金森病的治疗开发了新的因达系列,克服了以前的安全性和大脑透挑战. 这一新系列为增强中枢神经系统向提供了改进的类似药物的特性.

科学领域:

药用化学医学化学
神经科学是一个神经科学.
药物发现药物发现药物发现

背景情况:

氨酸丰富的重复激酶2 (LRRK2) 抑制是帕金森病的一种有前途的治疗策略,由遗传证据支持.
以前的因达化合物表现出安全问题和不良的大脑透 (低Kp_u,u),阻碍了中央目标参与评估.

研究的目的:

发现结构上不同的,透中枢神经系统的因达基化合物,具有改进的类似药物的特性.
为解决与早期的化合物相关的安全性和转化风险,用于帕金森病治疗.

主要方法:

采用基于结构和财产的药物设计原则.
进行了扩展的流量输送器分析,以评估血脑屏障的透性.
优先考虑结构多样性,以减轻来源不明的安全风险.

主要成果:

成功开发了一种"重新发明"的英达系列,具有显著增强的物理化学特性.
获得了改善的流量输送器配置文件,表明更好的中枢神经系统药物相似性.
保持对LRRK2标的高强度和优异的非标激酶选择性.

结论:

重新发明的英达系列代表了对帕金森病LRRK2抑制剂开发的有希望的进步.
化合物23是一种先进的头,证明了对中枢神经系统导向治疗的有利概况,克服了之前的局限性.

更多相关视频

Human Peripheral Blood Neutrophil Isolation for Interrogating the Parkinson's Associated LRRK2 Kinase Pathway by Assessing Rab10 Phosphorylation

Human Peripheral Blood Neutrophil Isolation for Interrogating the Parkinson's Associated LRRK2 Kinase Pathway by Assessing Rab10 Phosphorylation

Published on: March 21, 2020

Development of Inhibitors of Protein-protein Interactions through REPLACE: Application to the Design and Development Non-ATP Competitive CDK Inhibitors

Development of Inhibitors of Protein-protein Interactions through REPLACE: Application to the Design and Development Non-ATP Competitive CDK Inhibitors

Published on: October 26, 2015

相关概念视频

Drug Discovery: Overview

Drug Discovery: Overview

Drug discovery is a multifaceted process involving extensive screening, testing, and optimization of lead compounds to identify potential new drugs for therapeutic use. It combines several approaches, including screening large numbers of natural products, chemical modification of known active molecules, identification of new drug targets, and rational design based on biological mechanisms and drug-receptor structure. These approaches are carried out in both academic research laboratories and...

Structure-Activity Relationships and Drug Design

Structure-Activity Relationships and Drug Design

Drug design is a dynamic field that involves discovering and developing new medications based on specific biological targets. This process heavily relies on structure-activity relationships (SAR) and quantitative structure-activity relationships (QSAR) to guide the design and optimization of efficient drugs.
SAR studies the intricate relationship between a drug's chemical structure and biological activity. It focuses on understanding how modifications to a drug's structure can influence...